HENDERSON, Nev., March 19,
2024 /PRNewswire/ -- VolitionRx Limited (NYSE
AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company,
has appointed Dr Andrew Retter as
its Chief Medical Officer, effective April
1, 2024.
Dr Retter will provide medical leadership at Volition and ensure
the company's scientific and clinical efforts are aligned with
patient needs.
Andrew is an Intensive Care Consultant at Guy's and St. Thomas'
NHS Foundation Trust in London,
where he has worked as a Consultant since 2014 and leads Clinical
Governance in Critical Care. He specializes in the management of
severe respiratory failure, ECMO and thrombosis. Dr Retter is
the only Consultant in the UK to hold dual entry on the specialist
register in Intensive Care and Haematology, and provides national
guidance on the management of complex haematology patients in
critical care.
Dr Retter has worked with Volition in an advisory capacity since
January 2022, to help guide the
product development and clinical utility of Nu.Q® NETs – a
CE-marked routine blood test to detect diseases associated with
NETosis, such as sepsis.
Cameron Reynolds, President and
Group Chief Executive Officer at Volition, said: "We are delighted
to welcome Andrew to Volition. Dr Retter is a leading expert in
Intensive Care Medicine and Haematology. As Chief Medical Officer
he will be vital to our success – ensuring the needs of the patient
are placed at the heart of our research, development and
commercialization activities."
Commenting on his appointment, Dr Retter said: "I'm joining
Volition as I believe the company has the potential to transform
healthcare through its range of cutting-edge diagnostic solutions
that are simple, cost-effective and scalable, making them suitable
for broad application in a variety of healthcare settings.
"In the healthcare profession, our goal is to detect disease
early, rapidly treat patients and then be able to monitor treatment
response. Volition's pioneering technology has the potential to do
just that, and to significantly improve patient outcomes."
Volition is developing simple, easy-to-use, cost-effective blood
tests to help diagnose and monitor a range of life-altering
diseases including some cancers and diseases associated with
NETosis such as sepsis. For more information about Volition's
technology go to: www.volition.com
About Volition
Volition is a multi-national epigenetics company focused on
advancing the science of epigenetics. Volition is dedicated to
saving lives and improving outcomes for people and animals with
life-altering diseases through earlier detection, as well as
disease and treatment monitoring.
Through its subsidiaries, Volition is developing and
commercializing simple, easy to use, cost-effective blood tests to
help diagnose and monitor a range of diseases, including some
cancers and diseases associated with NETosis, such as sepsis. Early
diagnosis and monitoring have the potential not only to prolong the
life of patients, but also improve their quality of life.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
The contents found at Volition's website address are not
incorporated by reference into this document and should not be
considered part of this document. Such website address is
included in this document as an inactive textual reference
only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition,
mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, the effectiveness of Volition's blood-based
diagnostic, prognostic and disease monitoring tests, and Volition's
ability to develop and successfully commercialize such test
platforms for early detection of cancer and other diseases as well
as serving as a diagnostic, prognostic or disease monitoring tools
for such diseases. Volition's actual results may differ materially
from those indicated in these forward-looking statements due to
numerous risks and uncertainties, including, without limitation,
results of studies testing the efficacy of its tests. For instance,
if Volition fails to develop and commercialize diagnostic,
prognostic or disease monitoring products, it may be unable to
execute its plan of operations. Other risks and uncertainties
include Volition's failure to obtain necessary regulatory
clearances or approvals to distribute and market future products; a
failure by the marketplace to accept the products in Volition's
development pipeline or any other diagnostic, prognostic or disease
monitoring products Volition might develop; Volition's failure to
secure adequate intellectual property protection; Volition will
face fierce competition and Volition's intended products may become
obsolete due to the highly competitive nature of the diagnostics
and disease monitoring market and its rapid technological change;
downturns in domestic and foreign economies; and other risks
identified in Volition's most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, as well as other documents that
Volition files with the Securities and Exchange Commission. These
statements are based on current expectations, estimates and
projections about Volition's business based, in part, on
assumptions made by management. These statements are not guarantees
of future performance and involve risks, uncertainties and
assumptions that are difficult to predict. Forward-looking
statements are made as of the date of this release, and, except as
required by law, Volition does not undertake an obligation to
update its forward-looking statements to reflect future events or
circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are
trademarks and/or service marks of VolitionRx Limited and its
subsidiaries.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/volition-appoints-dr-andrew-retter-as-chief-medical-officer-302093380.html
SOURCE VolitionRx Limited